214 related articles for article (PubMed ID: 32798602)
21. Chemically Modified Human Serum Albumin Potently Blocks Entry of Ebola Pseudoviruses and Viruslike Particles.
Li H; Yu F; Xia S; Yu Y; Wang Q; Lv M; Wang Y; Jiang S; Lu L
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167539
[TBL] [Abstract][Full Text] [Related]
22. Development of therapeutics for treatment of Ebola virus infection.
Li H; Ying T; Yu F; Lu L; Jiang S
Microbes Infect; 2015 Feb; 17(2):109-17. PubMed ID: 25498866
[TBL] [Abstract][Full Text] [Related]
23. Evidence for distinct mechanisms of small molecule inhibitors of filovirus entry.
Schafer A; Xiong R; Cooper L; Nowar R; Lee H; Li Y; Ramirez BE; Peet NP; Caffrey M; Thatcher GRJ; Saphire EO; Cheng H; Rong L
PLoS Pathog; 2021 Feb; 17(2):e1009312. PubMed ID: 33539432
[TBL] [Abstract][Full Text] [Related]
24. Assessing Antiviral Countermeasures Using Mouse Models of Ebolavirus Infection.
Kroeker A; Griffin BD; Qiu X; Kobinger G
Methods Mol Biol; 2017; 1628():273-282. PubMed ID: 28573628
[TBL] [Abstract][Full Text] [Related]
25. Clomiphene and Its Isomers Block Ebola Virus Particle Entry and Infection with Similar Potency: Potential Therapeutic Implications.
Nelson EA; Barnes AB; Wiehle RD; Fontenot GK; Hoenen T; White JM
Viruses; 2016 Aug; 8(8):. PubMed ID: 27490565
[TBL] [Abstract][Full Text] [Related]
26. Identification of entry inhibitors of Ebola virus pseudotyped vectors from a myxobacterial compound library.
Beck S; Henß L; Weidner T; Herrmann J; Müller R; Chao YK; Grimm C; Weber C; Sliva K; Schnierle BS
Antiviral Res; 2016 Aug; 132():85-91. PubMed ID: 27241689
[TBL] [Abstract][Full Text] [Related]
27. Repurposing Antimalarials to Tackle the COVID-19 Pandemic.
Krishna S; Augustin Y; Wang J; Xu C; Staines HM; Platteeuw H; Kamarulzaman A; Sall A; Kremsner P
Trends Parasitol; 2021 Jan; 37(1):8-11. PubMed ID: 33153922
[TBL] [Abstract][Full Text] [Related]
28. Learning from COVID-19: How drug hunters can prepare for the next pandemic.
Puhl AC; Lane TR; Ekins S
Drug Discov Today; 2023 Oct; 28(10):103723. PubMed ID: 37482237
[TBL] [Abstract][Full Text] [Related]
29. Two Distinct Lysosomal Targeting Strategies Afford Trojan Horse Antibodies With Pan-Filovirus Activity.
Wirchnianski AS; Wec AZ; Nyakatura EK; Herbert AS; Slough MM; Kuehne AI; Mittler E; Jangra RK; Teruya J; Dye JM; Lai JR; Chandran K
Front Immunol; 2021; 12():729851. PubMed ID: 34721393
[TBL] [Abstract][Full Text] [Related]
30. Ebola Virus Bayesian Machine Learning Models Enable New in Vitro Leads.
Anantpadma M; Lane T; Zorn KM; Lingerfelt MA; Clark AM; Freundlich JS; Davey RA; Madrid PB; Ekins S
ACS Omega; 2019 Jan; 4(1):2353-2361. PubMed ID: 30729228
[TBL] [Abstract][Full Text] [Related]
31. Small molecule inhibitors of ebola virus infection.
Picazo E; Giordanetto F
Drug Discov Today; 2015 Feb; 20(2):277-86. PubMed ID: 25532798
[TBL] [Abstract][Full Text] [Related]
32. Tetherin Inhibits Nipah Virus but Not Ebola Virus Replication in Fruit Bat Cells.
Hoffmann M; Nehlmeier I; Brinkmann C; Krähling V; Behner L; Moldenhauer AS; Krüger N; Nehls J; Schindler M; Hoenen T; Maisner A; Becker S; Pöhlmann S
J Virol; 2019 Feb; 93(3):. PubMed ID: 30429347
[TBL] [Abstract][Full Text] [Related]
33. Transporter Inhibition Profile for the Antivirals Tilorone, Quinacrine and Pyronaridine.
Vignaux PA; Lane TR; Puhl AC; Hau RK; Wright SH; Cherrington NJ; Ekins S
ACS Omega; 2023 Apr; 8(13):12532-12537. PubMed ID: 37033868
[TBL] [Abstract][Full Text] [Related]
34. The Natural Product Eugenol Is an Inhibitor of the Ebola Virus In Vitro.
Lane T; Anantpadma M; Freundlich JS; Davey RA; Madrid PB; Ekins S
Pharm Res; 2019 May; 36(7):104. PubMed ID: 31101988
[TBL] [Abstract][Full Text] [Related]
35. Targeting Ebola virus replication through pharmaceutical intervention.
Hansen F; Feldmann H; Jarvis MA
Expert Opin Investig Drugs; 2021 Mar; 30(3):201-226. PubMed ID: 33593215
[No Abstract] [Full Text] [Related]
36. Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists.
Cheng H; Lear-Rooney CM; Johansen L; Varhegyi E; Chen ZW; Olinger GG; Rong L
J Virol; 2015 Oct; 89(19):9932-8. PubMed ID: 26202243
[TBL] [Abstract][Full Text] [Related]
37. Suramin is a potent inhibitor of Chikungunya and Ebola virus cell entry.
Henß L; Beck S; Weidner T; Biedenkopf N; Sliva K; Weber C; Becker S; Schnierle BS
Virol J; 2016 Aug; 13(1):149. PubMed ID: 27581733
[TBL] [Abstract][Full Text] [Related]
38. Antiviral Screening of Multiple Compounds against Ebola Virus.
Dowall SD; Bewley K; Watson RJ; Vasan SS; Ghosh C; Konai MM; Gausdal G; Lorens JB; Long J; Barclay W; Garcia-Dorival I; Hiscox J; Bosworth A; Taylor I; Easterbrook L; Pitman J; Summers S; Chan-Pensley J; Funnell S; Vipond J; Charlton S; Haldar J; Hewson R; Carroll MW
Viruses; 2016 Oct; 8(11):. PubMed ID: 27801778
[TBL] [Abstract][Full Text] [Related]
39. Identification of Ellagic Acid from Plant Rhodiola rosea L. as an Anti-Ebola Virus Entry Inhibitor.
Cui Q; Du R; Anantpadma M; Schafer A; Hou L; Tian J; Davey RA; Cheng H; Rong L
Viruses; 2018 Mar; 10(4):. PubMed ID: 29584652
[TBL] [Abstract][Full Text] [Related]
40. Combinatorial screening of a panel of FDA-approved drugs identifies several candidates with anti-Ebola activities.
Du X; Zuo X; Meng F; Wu F; Zhao X; Li C; Cheng G; Qin FX
Biochem Biophys Res Commun; 2020 Feb; 522(4):862-868. PubMed ID: 31806372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
